Related Experiment Video
Updated: Jun 27, 2026

Assessing Functional Performance in the Mdx Mouse Model
Published on: March 28, 2014
Functional border-associated macrophages limit Alzheimer's Disease progression
Drew Adler1,2,3, Natália Pinheiro-Rosa2, Alon Millet4,5
1Vilcek Institute of Graduate Biomedical Sciences, New York University Grossman School of Medicine; New York, NY, USA.
Abstract:
Brain-resident macrophages are known to play numerous roles in the progression of Alzheimer's Disease (AD). However, the relative contribution of microglia and border-associated macrophages (BAM) to AD pathogenesis has been difficult to disentangle. We recently identified Maf, a newly described AD GWAS gene, as essential for BAM, but not microglial, survival. By crossing BAM depleted mice with the 5xFAD AD model, we found stark evidence of cerebral amyloid angiopathy (CAA), increased overall β-amyloid burden, accelerated markers of neurodegeneration, and early memory deficits. In the healthy brain, BAM take up more β-amyloid per cell than microglia. However, as disease progresses, both in human AD patient samples and model AD mice, BAM number is reduced, and the remaining BAMs display impaired endocytic capacity, and show signs of metabolic exhaustion at an earlier age than microglia. Thus, strategies to preserve or restore BAM function represents a novel therapeutic avenue for AD and CAA.
Insights
Border-associated macrophages (BAMs) are crucial in Alzheimer's Disease (AD) and cerebral amyloid angiopathy (CAA). Preserving BAM function offers a new therapeutic strategy for these neurodegenerative conditions.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Brain-resident macrophages, including microglia and border-associated macrophages (BAMs), are implicated in Alzheimer's Disease (AD) pathogenesis.
- Disentangling the specific roles of microglia versus BAMs in AD has been challenging.
- The gene Maf, identified through AD GWAS studies, is critical for BAM survival but not microglial survival.
Purpose of the Study:
- To investigate the contribution of BAMs to Alzheimer's Disease (AD) and cerebral amyloid angiopathy (CAA) progression.
- To explore the functional changes in BAMs during AD pathogenesis.
- To evaluate the therapeutic potential of preserving BAM function in AD.
Main Methods:
- Utilized BAM-depleted mice crossed with the 5xFAD AD model.
- Analyzed markers of cerebral amyloid angiopathy (CAA), beta-amyloid burden, and neurodegeneration.
- Assessed BAM and microglial endocytic capacity and metabolic state in AD models and human samples.
Main Results:
- BAM depletion in AD models exacerbated cerebral amyloid angiopathy (CAA), increased beta-amyloid load, and accelerated neurodegeneration and memory deficits.
- In healthy brains, BAMs exhibit higher beta-amyloid uptake than microglia.
- During AD progression, BAMs show reduced numbers, impaired endocytic function, and metabolic exhaustion earlier than microglia.
Conclusions:
- BAMs play a critical protective role in mitigating AD and CAA pathology.
- BAM dysfunction, characterized by reduced numbers and impaired phagocytic capacity, contributes significantly to AD progression.
- Strategies aimed at preserving or restoring BAM function represent a promising novel therapeutic avenue for Alzheimer's Disease and cerebral amyloid angiopathy.
More Related Videos
Related Concept Videos
Microtubule Associated Proteins (MAPs)
Microtubule Instability
Regulation of Metabolism
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenomics: Identification of New Drug Targets

